SARS-CoV-2-IN-39 is a small molecule inhibitor with antiviral activity against SARS-CoV-2, exhibiting an EC50 of 1 µM. Its mechanism involves SKP2 inhibition and subsequent BECN1 stabilization, making it a useful research tool for studying autophagy and viral replication in vitro.